# US 2021/0260069 A1 · IRE1a INHIBITOR IN COMBINATION WITH CANCER THERAPEUTIC AGENT FOR CANCER TREATMENT

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0260069 A1
- Document ID: US20210260069A1
- Status: Published application
- Kind: A1
- Application number: 17/261,413
- Filed: 2019-07-23
- Published: 2021-08-26
- Earliest claimed: 2018-07-23
- Assignees: Fosun Orinove Pharmatech, Inc.
- Applicants: Fosun Orinove PharmaTech, Inc.
- Inventors: Qingping ZENG; John PATTERSON; Stephanie GREENE
- Web page: https://patentgrep.com/patent/US20210260069A1

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4412: having oxo groups directly attached to the heterocyclic ring
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are a pharmaceutical combination comprising an IRE1α inhibitor and one or more additional cancer therapeutic agents for the treatment of cancerous tumor, a pharmaceutical composition containing the same and a method for treating cancerous tumor using the same.

## Claims

### Claim 1

A pharmaceutical combination, comprising
(a) a compound of formula (I) or a pharmaceutically acceptable salt thereof, and (b) one or more additional cancer therapeutic agents:
wherein
R3 and R4 are independently hydrogen or C1-6 alkoxyl, which is optionally substituted with one or more substituents selected from the group consisting of (1) C1-C6 hydrocarbon chain containing N or O atom, and (2) C3-10 cycloalkyl, which optionally contains 1 or 2 heteroatoms independently selected from the group consisting of N, O, and S;
R5 is hydrogen, C1-6 alkyl, C1-6 alkoxyl, or C1-6 alkylamino;
R6 is C1-6 alkyl, which is substituted with 1, 2 or 3 substituents independently selected from the group consisting of C1-6 alkoxyl, C1-6 hydroxylalkyl, C1-6 alkoxyl C1-6alkyl,
R9 and R10 are independently hydrogen; C1-6 alkyl; C1-6 alkoxyl C1-6 alkyl; perfluoro C1-6alkoxyl C1-6alkyl; or
R9 and R10 together with the nitrogen atom to which they are attached form a heterocycle containing 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S, and the heterocycle is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of C1-6 alkyl, C1-6 alkylamino, C1-6 alkoxyl.

### Claim 2 (depends on 1)

The pharmaceutical combination according to claim 1, wherein
the additional cancer therapeutic agent has at least one of the following features:
(1) inducing ER stress;
(2) inducing or up-regulating IRE-1α expression;
(3) inducing or up-regulating XBP1 splicing; and
(4) being less effective when IRE-1α is expressed.

### Claim 3 (depends on 1)

The pharmaceutical combination according to claim 1, wherein the compound of formula (I) or the pharmaceutically acceptable salt thereof and one or more additional cancer therapeutic agents are administered simultaneously, separately or sequentially.

### Claim 4 (depends on 1)

The pharmaceutical combination according to claim 1, wherein
the compound of formula (I) has formula (II)

### Claim 5 (depends on 1)

The pharmaceutical combination according to claim 1, wherein
the pharmaceutical combination is in the form of a pharmaceutical composition or a kit.

### Claim 6 (depends on 1)

The pharmaceutical combination according to claim 1, wherein
the additional cancer therapeutic agent is selected from the group consisting of
cytotoxic chemotherapeutic agents; antimetabolites; antimitotic agents; alkylating agents; DNA damaging agents; antitumor antibiotics; platinum coordination complexes; proteasome inhibitors; HSP90 inhibitors; hormones and hormone analogs; aromatase inhibitors; fibrinolytic agents; antimigratory agents; antisecretory agents; immunosuppressives; anti-angiogenic compounds and vascular endothelial growth factor inhibitors; fibroblast growth factor inhibitors; epidermal growth factor receptor inhibitors; antibodies; checkpoint inhibitors; cell cycle inhibitors and differentiation inducers; mTOR inhibitors; corticosteroids; growth factor signal transduction kinase inhibitors; mitochondrial dysfunction inducers; caspase activators; chromatin disruptors and DNA repair enzyme inhibitors; HDAC inhibitors; Bcr-Abl inhibitors; FMS-like tyrosine kinase 3 (Flt3) inhibitors; and preferably selected from the group consisting of lestaurtinib, nilotinib, sorafenib, dasatinib, gefitinib, temisirolimus, vatalinib, Torisel®, vorinostat, paclitaxel, gemcitabine, 17-AAG, Velcade®, tamoxifen, temozolomide; or selected from the group consisting of sorafenib, eribulin, cyclophosphamide, 5-fluorouracil, carboplatin, doxorubicin, anastrozole; more preferably selected from the group consisting of paclitaxel, Velcade®, tamoxifen and temozolomide; or selected from the group consisting of sorafenib, eribulin, cyclophosphamide, 5-fluorouracil, carboplatin, doxorubicin.

### Claim 7 (depends on 6)

The pharmaceutical combination according to claim 6, wherein
the additional cancer therapeutic agent is sorafenib;
or
the additional cancer therapeutic agent is selected from the group consisting of
(i) microtubule disruptor, wherein said microtubule disruptor is selected from taxane and eribulin, and said taxane is selected from paclitaxel, docetaxel, cabazitaxel and albumin-bound paclitaxel, preferably paclitaxel and docetaxel, more preferably paclitaxel;
(ii) cyclophosphamide;
(iii) 5-fluorouracil;
(iv) carboplatin;
(v) doxorubicin;
or
the additional cancer therapeutic agent is selected from the group consisting of
(i) microtubule disruptor, wherein said taxane is selected from paclitaxel, docetaxel, cabazitaxel and albumin-bound paclitaxel, preferably paclitaxel and docetaxel, more preferably paclitaxel;
(ii) aromatase inhibitor, wherein said aromatase inhibitor is selected from letrozole and anastrozole;
(iii) tamoxifen;
or
the additional cancer therapeutic agent is taxane, wherein said taxane is selected from paclitaxel, docetaxel, cabazitaxel and albumin-bound paclitaxel, preferably paclitaxel and docetaxel, more preferably paclitaxel.

### Claim at position 8

-10. (canceled)

### Claim 11 (depends on 1)

A kit or a pharmaceutical composition, comprising the pharmaceutical combination according to claim 1.

### Claim 12 (depends on 11)

A method for treating cancerous tumor, comprising administering a subject in need thereof an effective amount of the kit or pharmaceutical composition according to claim 11.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the cancerous tumor is selected from the group consisting of liver cancer, triple negative breast cancer, estrogen positive breast cancer, ovarian carcinoma, pancreatic cancer, head and neck cancer, non-small cell lung cancer, glioblastoma, for example glioblastoma multiforme, and multiple myeloma.

### Claim 14 (depends on 12)

The method according to claim 12, wherein the compound of formula (I) or the pharmaceutically acceptable salt thereof and one or more additional cancer therapeutic agents are administered simultaneously, separately or sequentially.

### Claim 15 (depends on 12)

The method according to claim 12, wherein
the cancerous tumor is liver tumor, preferably hepatocellular carcinoma; and
the additional cancer therapeutic agent is sorafenib.

### Claim 16 (depends on 12)

The method according to claim 12, wherein
the cancerous tumor is breast cancer, preferably triple negative breast cancer; and
the additional cancer therapeutic agent is selected from
(i) microtubule disruptor, wherein said microtubule disruptor is selected from taxane and eribulin, and said taxane is selected from paclitaxel, docetaxel, cabazitaxel and albumin-bound paclitaxel, preferably paclitaxel and docetaxel, more preferably paclitaxel;
(ii) cyclophosphamide;
(iii) 5-fluorouracil;
(iv) carboplatin;
(v) doxorubicin;
or
the cancerous tumor is breast cancer, preferably estrogen positive breast cancer, more preferably Her2 negative and estrogen positive metastatic breast cancer; and
the additional cancer therapeutic agent is selected from
(i) microtubule disruptor, wherein said taxane is selected from paclitaxel, docetaxel, cabazitaxel and albumin-bound paclitaxel, preferably paclitaxel and docetaxel, more preferably paclitaxel;
(ii) aromatase inhibitor, wherein said aromatase inhibitor is selected from letrozole and anastrozole;
(iii) tamoxifen;
or
the cancerous tumor is esophagus cancer (preferably esophageal squamous cell cancer), ovarian cancer, non-small cell lung cancer, or glioblastoma; and
the additional cancer therapeutic agent is taxane, wherein said taxane is selected from paclitaxel, docetaxel, cabazitaxel and albumin-bound paclitaxel, preferably paclitaxel and docetaxel, more preferably paclitaxel.

### Claim at position 15

-18. (canceled)

### Claim 19

A method for enhancing the efficacy of a cancer therapeutic agent,
comprising applying the compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with the cancer therapeutic agent,
wherein
R3 and R4 are independently hydrogen or C1-6 alkoxyl, which is optionally substituted with one or more substituents selected from the group consisting of (1) C1-C6 hydrocarbon chain containing N or O atom, and (2) C3-10 cycloalkyl, which optionally contains 1 or 2 heteroatoms independently selected from the group consisting of N, O, and S;
R5 is hydrogen, C1-6 alkyl, C1-6 alkoxyl, or C1-6 alkylamino;
R6 is C1-6 alkyl, which is substituted with 1, 2 or 3 substituents independently selected from the group consisting of C1-6 alkoxyl, C1-6 hydroxylalkyl, C1-6 alkoxyl C1-6alkyl,
R9 and R10 are independently hydrogen; C1-6 alkyl; C1-6 alkoxyl C1-6 alkyl; perfluoro C1-6 alkoxyl C1-6alkyl; or
R9 and R10 together with the nitrogen atom to which they are attached form a heterocycle containing 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S, and the heterocycle is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of C1-6 alkyl, C1-6 alkylamino, C1-6 alkoxyl.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the cancer therapeutic agent has at least one of the following features:
(1) inducing ER stress;
(2) inducing or up-regulating IRE-1α expression;
(3) inducing or up-regulating XBP1 splicing; and
(4) being less effective when IRE-1α is expressed.

### Claim 21 (depends on 19)

The method according to claim 19, wherein the compound of formula (I) or the pharmaceutically acceptable salt thereof and one or more additional cancer therapeutic agents are administered simultaneously, separately or sequentially.

### Claim 22 (depends on 19)

The method according to claim 19, wherein
the compound of formula (I) has formula (II)

### Claim 23 (depends on 19)

The method according to claim 19, wherein the cancer therapeutic agent is selected from the group consisting of cytotoxic chemotherapeutic agents; antimetabolites; antimitotic agents; alkylating agents; DNA damaging agents; antitumor antibiotics; platinum coordination complexes; proteasome inhibitors; HSP90 inhibitors; hormones and hormone analogs; aromatase inhibitors; fibrinolytic agents; antimigratory agents; antisecretory agents; immunosuppressives; anti-angiogenic compounds and vascular endothelial growth factor inhibitors; fibroblast growth factor inhibitors; epidermal growth factor receptor inhibitors; antibodies; checkpoint inhibitors; cell cycle inhibitors and differentiation inducers; mTOR inhibitors; corticosteroids; growth factor signal transduction kinase inhibitors; mitochondrial dysfunction inducers; caspase activators; chromatin disruptors and DNA repair enzyme inhibitors; HDAC inhibitors; Bcr-Abl inhibitors; FMS-like tyrosine kinase 3 (Flt3) inhibitors; and preferably selected from the group consisting of lestaurtinib, nilotinib, sorafenib, dasatinib, gefitinib, temisirolimus, vatalinib, Torisel®, vorinostat, paclitaxel, gemcitabine, 17-AAG, Velcade®, tamoxifen, temozolomide; or selected from the group consisting of sorafenib, eribulin, cyclophosphamide, 5-fluorouracil, carboplatin, doxorubicin, anastrozole; more preferably selected from the group consisting of paclitaxel, Velcade®, tamoxifen and temozolomide; or selected from the group consisting of sorafenib, eribulin, cyclophosphamide, 5-fluorouracil, carboplatin, doxorubicin.

### Claim 24 (depends on 19)

The method according to claim 19, wherein the cancer therapeutic agent is used for treatment of cancerous tumor selected from the group consisting of liver cancer, triple negative breast cancer, estrogen positive breast cancer, ovarian carcinoma, pancreatic cancer, head and neck cancer, non-small cell lung cancer, glioblastoma, for example glioblastoma multiforme, and multiple myeloma.

### Claim 25 (depends on 19)

The method according to claim 19, wherein
the cancer therapeutic agent is sorafenib; and
the cancer is liver tumor, preferably hepatocellular carcinoma.

### Claim 26 (depends on 19)

The method according to claim 19, wherein
the cancer therapeutic agent is selected from
(i) microtubule disruptor, wherein said microtubule disruptor is selected from taxane and eribulin, and said taxane is selected from paclitaxel, docetaxel, cabazitaxel and albumin-bound paclitaxel, preferably paclitaxel and docetaxel, more preferably paclitaxel;
(ii) cyclophosphamide;
(iii) 5-fluorouracil;
(iv) carboplatin;
(v) doxorubicin; and
the cancer is breast cancer, preferably triple negative breast cancer,
or
the cancer therapeutic agent is selected from
(i) microtubule disruptor, wherein said taxane is selected from paclitaxel, docetaxel, cabazitaxel and albumin-bound paclitaxel, preferably paclitaxel and docetaxel, more preferably paclitaxel;
(ii) aromatase inhibitor, wherein said aromatase inhibitor is selected from letrozole and anastrozole;
(iii) tamoxifen; and
the cancer is breast cancer, preferably estrogen positive breast cancer, more preferably Her2 negative and estrogen positive metastatic breast cancer;
or
the cancer therapeutic agent is selected from taxane, wherein said taxane is selected from paclitaxel, docetaxel, cabazitaxel and albumin-bound paclitaxel, preferably paclitaxel and docetaxel, more preferably paclitaxel; and
the cancer is esophagus cancer (preferably esophageal squamous cell cancer), ovarian cancer, lung cancer (preferably non-small cell lung cancer), or glioblastoma.

### Claim at position 24

-28. (canceled)

### Claim 29

A method for treating cancerous tumors, comprising administering a subject in need thereof an effective amount of formula (I) or a pharmaceutically acceptable salt thereof:
wherein
R3 and R4 are independently hydrogen or C1-6 alkoxyl, which is optionally substituted with one or more substituents selected from the group consisting of (1) C1-C6 hydrocarbon chain containing N or O atom, and (2) C3-10 cycloalkyl, which optionally contains 1 or 2 heteroatoms independently selected from the group consisting of N, O, and S;
R5 is hydrogen, C1-6 alkyl, C1-6 alkoxyl, or C1-6 alkylamino;
R6 is C1-6 alkyl, which is substituted with 1, 2 or 3 substituents independently selected from the group consisting of C1-6 alkoxyl, C1-6 hydroxylalkyl, C1-6 alkoxyl C1-6alkyl,
R9 and R10 are independently hydrogen; C1-6 alkyl; C1-6 alkoxyl C1-6 alkyl; perfluoro C1-6alkoxyl C1-6alkyl; or
R9 and R10 together with the nitrogen atom to which they are attached form a heterocycle containing 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O, and S, and the heterocycle is optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of C1-6 alkyl, C1-6 alkylamino, C1-6 alkoxyl;
and one or more additional cancer therapeutic agents.

### Claim 30 (depends on 29)

The method according to claim 29, wherein the cancer therapeutic agent has at least one of the following features:
(1) inducing ER stress;
(2) inducing or up-regulating IRE-1α expression;
(3) inducing or up-regulating XBP1 splicing; and
(4) being less effective when IRE-1α is expressed.

### Claim 31 (depends on 29)

The method according to claim 29, wherein the compound of formula (I) or the pharmaceutically acceptable salt thereof and one or more additional cancer therapeutic agents are administered simultaneously, separately or sequentially.

### Claim 32 (depends on 29)

The method according to claim 29, wherein the compound of formula (I) has formula (II)

### Claim 33 (depends on 29)

The method according to claim 29, wherein the cancer therapeutic agent is selected from the group consisting of cytotoxic chemotherapeutic agents; antimetabolites; antimitotic agents; alkylating agents; DNA damaging agents; antitumor antibiotics; platinum coordination complexes; proteasome inhibitors; HSP90 inhibitors; hormones and hormone analogs; aromatase inhibitors; fibrinolytic agents; antimigratory agents; antisecretory agents; immunosuppressives; anti-angiogenic compounds and vascular endothelial growth factor inhibitors; fibroblast growth factor inhibitors; epidermal growth factor receptor inhibitors; antibodies; checkpoint inhibitors; cell cycle inhibitors and differentiation inducers; mTOR inhibitors; corticosteroids; growth factor signal transduction kinase inhibitors; mitochondrial dysfunction inducers; caspase activators; chromatin disruptors and DNA repair enzyme inhibitors; HDAC inhibitors; Bcr-Abl inhibitors; FMS-like tyrosine kinase 3 (Flt3) inhibitors; and preferably selected from the group consisting of lestaurtinib, nilotinib, sorafenib, dasatinib, gefitinib, temisirolimus, vatalinib, Torisel®, vorinostat, paclitaxel, gemcitabine, 17-AAG, Velcade®, tamoxifen, temozolomide; or selected from the group consisting of sorafenib, eribulin, cyclophosphamide, 5-fluorouracil, carboplatin, doxorubicin, anastrozole; more preferably selected from the group consisting of paclitaxel, Velcade®, tamoxifen and temozolomide; or selected from the group consisting of sorafenib, eribulin, cyclophosphamide, 5-fluorouracil, carboplatin, doxorubicin.

### Claim 34 (depends on 29)

The method according to claim 29, wherein the cancerous tumor is selected from the group consisting of liver cancer, triple negative breast cancer, estrogen positive breast cancer, ovarian carcinoma, pancreatic cancer, head and neck cancer, non-small cell lung cancer, glioblastoma, for example glioblastoma multiforme and multiple myeloma.

### Claim 35 (depends on 29)

The method according to claim 29, wherein
the cancerous tumor is liver tumor, preferably hepatocellular carcinoma; and
the additional cancer therapeutic agent is sorafenib.

### Claim 36 (depends on 29)

The method according to claim 29, wherein
the cancerous tumor is breast cancer, preferably triple negative breast cancer; and
the additional cancer therapeutic agent is selected from
(i) microtubule disruptor, wherein said microtubule disruptor is selected from taxane and eribulin, and said taxane is selected from paclitaxel, docetaxel, cabazitaxel and albumin-bound paclitaxel, preferably paclitaxel and docetaxel, more preferably paclitaxel;
(ii) cyclophosphamide;
(iii) 5-fluorouracil;
(iv) carboplatin;
(v) doxorubicin;
or
the cancerous tumor is breast cancer, preferably estrogen positive breast cancer, more preferably Her2 negative and estrogen positive metastatic breast cancer; and
the additional cancer therapeutic agent is selected from
(i) microtubule disruptor, wherein said taxane is selected from paclitaxel, docetaxel, cabazitaxel and albumin-bound paclitaxel, preferably paclitaxel and docetaxel, more preferably paclitaxel;
(ii) aromatase inhibitor, wherein said aromatase inhibitor is selected from letrozole and anastrozole;
(iii) tamoxifen;
or
the cancerous tumor is esophagus cancer (preferably esophageal squamous cell cancer), ovarian cancer, lung cancer (preferably non-small cell lung cancer), or glioblastoma; and
the additional cancer therapeutic agent is taxane, wherein said taxane is selected from paclitaxel, docetaxel, cabazitaxel and albumin-bound paclitaxel, preferably paclitaxel and docetaxel, more preferably paclitaxel.

### Claim at position 33

-38. (canceled)
